X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with GREENPLY IND - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs GREENPLY IND - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES GREENPLY IND INDOCO REMEDIES/
GREENPLY IND
 
P/E (TTM) x 38.3 17.0 224.9% View Chart
P/BV x 3.0 3.8 79.6% View Chart
Dividend Yield % 0.8 1.6 45.9%  

Financials

 INDOCO REMEDIES   GREENPLY IND
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
GREENPLY IND
Mar-14
INDOCO REMEDIES/
GREENPLY IND
5-Yr Chart
Click to enlarge
High Rs360524 68.8%   
Low Rs249300 83.0%   
Sales per share (Unadj.) Rs119.0918.3 13.0%  
Earnings per share (Unadj.) Rs8.448.7 17.2%  
Cash flow per share (Unadj.) Rs15.273.4 20.8%  
Dividends per share (Unadj.) Rs1.603.00 53.3%  
Dividend yield (eoy) %0.50.7 72.1%  
Book value per share (Unadj.) Rs70.7241.8 29.2%  
Shares outstanding (eoy) m92.1524.14 381.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.60.4 570.6%   
Avg P/E ratio x36.48.5 430.6%  
P/CF ratio (eoy) x20.05.6 356.3%  
Price / Book Value ratio x4.31.7 252.9%  
Dividend payout %19.16.2 310.6%   
Avg Mkt Cap Rs m28,0839,948 282.3%   
No. of employees `0006.05.2 115.3%   
Total wages/salary Rs m2,1672,211 98.0%   
Avg. sales/employee Rs Th1,817.04,236.4 42.9%   
Avg. wages/employee Rs Th359.0422.5 85.0%   
Avg. net profit/employee Rs Th127.7224.7 56.8%   
INCOME DATA
Net Sales Rs m10,96822,169 49.5%  
Other income Rs m4080 49.4%   
Total revenues Rs m11,00722,249 49.5%   
Gross profit Rs m1,5652,646 59.1%  
Depreciation Rs m633596 106.2%   
Interest Rs m62602 10.3%   
Profit before tax Rs m9091,528 59.5%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m139353 39.3%   
Profit after tax Rs m7711,176 65.6%  
Gross profit margin %14.311.9 119.5%  
Effective tax rate %15.323.1 66.1%   
Net profit margin %7.05.3 132.5%  
BALANCE SHEET DATA
Current assets Rs m5,7259,333 61.3%   
Current liabilities Rs m5,4548,908 61.2%   
Net working cap to sales %2.51.9 128.7%  
Current ratio x1.01.0 100.2%  
Inventory Days Days6270 89.0%  
Debtors Days Days7261 117.3%  
Net fixed assets Rs m5,3078,158 65.1%   
Share capital Rs m184121 152.7%   
"Free" reserves Rs m6,3315,709 110.9%   
Net worth Rs m6,5165,837 111.6%   
Long term debt Rs m1,3232,682 49.3%   
Total assets Rs m11,97018,201 65.8%  
Interest coverage x15.63.5 441.9%   
Debt to equity ratio x0.20.5 44.2%  
Sales to assets ratio x0.91.2 75.2%   
Return on assets %7.09.8 71.2%  
Return on equity %11.820.1 58.7%  
Return on capital %12.425.0 49.6%  
Exports to sales %012.6 0.0%   
Imports to sales %021.7 0.0%   
Exports (fob) Rs mNA2,797 0.0%   
Imports (cif) Rs mNA4,806 0.0%   
Fx inflow Rs m4,5072,797 161.2%   
Fx outflow Rs m1,1414,945 23.1%   
Net fx Rs m3,366-2,149 -156.6%   
CASH FLOW
From Operations Rs m8861,884 47.0%  
From Investments Rs m-1,706-1,702 100.2%  
From Financial Activity Rs m1,316-233 -564.2%  
Net Cashflow Rs m497-51 -977.6%  

Share Holding

Indian Promoters % 59.2 55.0 107.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 6.5 192.3%  
FIIs % 6.0 15.3 39.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 23.3 96.1%  
Shareholders   12,805 3,736 342.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   REDINGTON (INDIA)  IIFL HOLDINGS  COMPACT DISC  IL&FS INV. MANAGERS  CENTURY PLYBOARDS  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

GREENPLY IND Announces Quarterly Results (1QFY19); Net Profit Down 22.2% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, GREENPLY IND has posted a net profit of Rs 238 m (down 22.2% YoY). Sales on the other hand came in at Rs 4 bn (down 2.2% YoY). Read on for a complete analysis of GREENPLY IND's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY18); Net Profit Up 14.3% (Quarterly Result Update)

Jun 19, 2018 | Updated on Jun 19, 2018

For the quarter ended March 2018, INDOCO REMEDIES has posted a net profit of Rs 205 m (up 14.3% YoY). Sales on the other hand came in at Rs 3 bn (down 2.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Sep 19, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS